BioTime, Inc. Press Releases

BTX 
$4.2
*  
0.17
4.22%
Get BTX Alerts
*Delayed - data as of Jan. 29, 2015  -  Find a broker to begin trading BTX now
Exchange: AMEX
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
BioTime Announces Issuance of 14 New Patents in the Fields of Regenerative Medicine, Stem Cell Technology, and Cancer Therapy
1/26/2015 8:00:00 AM - Business Wire
▲8.25 % Price Change since this news event. The Volume Ratio is 2.06.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


BioTime Subsidiary OncoCyte Corporation Appoints William Annett to Its Board of Directors
1/12/2015 8:00:00 AM - Business Wire
▼-0.71 % Price Change since this news event. The Volume Ratio is 1.26.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


TransCanada Adds Eighth Solar Facility to Power Portfolio
12/29/2014 8:30:00 AM - Market Wire


BioTime Appoints Adi Mohanty Chief Operating Officer
12/29/2014 8:30:00 AM - Business Wire
▲11.11 % Price Change since this news event. The Volume Ratio is 1.06.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


BioTime Subsidiary ES Cell International and GE Healthcare Cross-License patents in the Field of Cell Assays for Drug Testing
12/15/2014 12:00:00 PM - Business Wire
▲34.19 % Price Change since this news event. The Volume Ratio is 1.01.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


BioTime, Inc. Subsidiary OncoCyte Corporation Completes Initial Enrollment of Clinical Study of Urine-Based Bladder Cancer Diagnostic
12/15/2014 11:00:00 AM - Business Wire
▲34.62 % Price Change since this news event. The Volume Ratio is 1.17.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


BioTime Appoints Angus C. Russell to Board of Directors
12/15/2014 8:38:00 AM - Business Wire


BioTime Appoints Angus C. Russell to Board of Directors
12/15/2014 8:38:00 AM - Business Wire
▲32.49 % Price Change since this news event. The Volume Ratio is 1.12.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


BioTime to Host Investor and Analyst Day on December 15, 2014
12/12/2014 2:30:00 PM - Business Wire
▲29.23 % Price Change since this news event. The Volume Ratio is 0.64.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


BioTime to Present at the LD Micro VII Conference
12/3/2014 8:30:00 PM - Business Wire
▲28.83 % Price Change since this news event. The Volume Ratio is 0.96.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Asterias Biotherapeutics Reports Third Quarter Financial and Operating Results
11/10/2014 4:01:00 PM - PR Newswire


BioTime Reports Third Quarter Results and Recent Progress
11/10/2014 8:58:00 AM - Business Wire
▲24.63 % Price Change since this news event. The Volume Ratio is 1.6.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


BioTime Receives Authorization to Begin Pivotal Human Clinical Trial of Renevia™ in Europe
11/4/2014 7:00:00 AM - Business Wire
▲22.81 % Price Change since this news event. The Volume Ratio is 0.35.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


BioTime’s Subsidiary Cell Cure Neurosciences Receives FDA Authorization to Initiate Phase I/IIa Trial of Embryonic Stem Cell-Derived OpRegen® for the Treatment of the Dry Form of Age-Related Macular Degeneration
11/3/2014 7:00:00 AM - Business Wire
▲23.89 % Price Change since this news event. The Volume Ratio is 0.98.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day